comparemela.com
Home
Live Updates
Denali Therapeutics Announces Robust Reduction in Neurofilament Light (NfL) with DNL310 (ETV:IDS) Treatment in MPS II (Hunter Syndrome) : comparemela.com
Denali Therapeutics Announces Robust Reduction in Neurofilament Light (NfL) with DNL310 (ETV:IDS) Treatment in MPS II (Hunter Syndrome)
Interim results demonstrate average reduction of 64% from baseline in serum NfL after 2 years of dosing with DNL310 in Phase 1/2 studyFDA has recommended assessment of NfL, a marker of neuroaxonal... | June 20, 2023
Related Keywords
United States
,
America
,
Joseph Muenzer
,
Laura Hansen
,
Henrik Zetterberg
,
Exchange Commission
,
European Medicines Agency
,
Drug Administration
,
Media Relations
,
Fast Track
,
North America
,
South America
,
Denali Hunter
,
Transport Vehicle
,
South San
,
Private Securities Litigation Reform Act
,
Chief Medical
,
Quarterly Reports
,
Fluid Biomarkers Reveals Lysosome Dysfunction
,
Media Contact
,
Denali Therapeutics Inc Stock Exchange
,
News
,
Information
,
Press Release
,
Interim
,
Results
,
Emonstrate
,
Average
,
Reduction
,
F
,
Rom
,
Baseline
,
N
,
Serum
,
Fl
,
After
,
,
Tears
,
Closing
,
Ith
,
Nl310
,
Hase
,
Tudyfda
,
Gas
,
Ecommended
,
Assessment
,
Marker
,
F Dnli Us24823r1059
,
comparemela.com © 2020. All Rights Reserved.